Interleukin-34 is expressed by giant cell tumours of bone and plays a key role in RANKL-induced osteoclastogenesis

被引:137
作者
Baud'Huin, Marc [2 ]
Renault, Romain [2 ]
Charrier, Celine [2 ]
Riet, Anne [2 ]
Moreau, Anne [3 ]
Brion, Regis [2 ]
Gouin, Francois [2 ,3 ]
Duplomb, Laurence [2 ,3 ]
Heymann, Dominique [1 ,2 ,3 ]
机构
[1] Univ Nantes, Fac Med, INSERM, UMR S 957, F-44035 Nantes 1, France
[2] Nantes Atlantique Univ, Univ Nantes, Lab Physiopathol Resorpt Osseuse & Therapie Tumeu, EA3822, F-44035 Nantes, France
[3] Hop Hotel Dieu, CHU, Nantes, France
关键词
giant cell tumours; IL-34; M-CSF; RANKL; osteoclast; bone resorption; primary bone tumours; COLONY-STIMULATING FACTOR; KAPPA-B LIGAND; ENDOTHELIAL GROWTH-FACTOR; RECEPTOR ACTIVATOR; IN-VITRO; OSTEOPROTEGERIN LIGAND; INHIBITORY FACTOR; M-CSF; DIFFERENTIATION; RESORPTION;
D O I
10.1002/path.2684
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Interleukin-34 (IL-34) is a newly discovered regulator of myeloid lineage differentiation, proliferation, and survival, acting via the macrophage-colony stimulating factor receptor (M-CSF receptor, c-fms). M-CSF, the main ligand for c-fms, is required for osteoclastogenesis and has been already identified as a critical contributor of the pathogenesis of giant cell tumours of bone (GCTs), tumours rich in osteoclasts. According to the key role of M-CSF in osteoclastogenesis and GCTs, the expression of IL-34 in human GCTs was first assessed. Quantitative analysis of IL-34 mRNA expression in 14 human GCTs revealed expression of this cytokine in GCTs as well as M-CSF and c-fms. Immunohistochemistry demonstrated that osteoclast-like cells exhibited a huge immunostaining for IL-34 and that mononuclear stromal cells were slightly positive for this protein. In contrast to osteoblasts, bone-resorbing osteoclasts showed very strong staining for IL-34, suggesting its potential role in the pathogenesis of GCTs by facilitating osteoclast formation. The role of IL-34 in osteoclastogenesis was then studied in murine and human models. IL-34 was able to support RANKL-induced osteoclastogenesis in the absence of M-CSF in all models. Multinucleated cells generated in the presence of IL-34 and RANKL expressed specific osteoclastic markers and resorbed dentine. IL-34 induced phosphorylation of ERK 1/2 and Akt through the activation of c-fms, as revealed by the inhibition of signalling by a specific c-fms tyrosine kinase inhibitor. Furthermore, IL-34 stimulated RANKL-induced osteoclastogenesis by promoting the adhesion and proliferation of osteoclast progenitors, and had no effect on osteoclast survival. Overall, these data reveal that IL-34 can be entirely substituted for M-CSF in RANKL-induced osteoclastogenesis, thus identifying a new biological activity for this cytokine and a contribution to the pathogenesis of GCTs. Copyright (C) 2010 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.
引用
收藏
页码:77 / 86
页数:10
相关论文
共 48 条
[41]   Giant cell tumor of bone [J].
Turcotte, RE .
ORTHOPEDIC CLINICS OF NORTH AMERICA, 2006, 37 (01) :35-+
[42]   Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes [J].
Vandesompele, Jo ;
De Preter, Katleen ;
Pattyn, Filip ;
Poppe, Bruce ;
Van Roy, Nadine ;
De Paepe, Anne ;
Speleman, Frank .
GENOME BIOLOGY, 2002, 3 (07)
[43]   Transgenic expression of CSF-1 in CSF-1 receptor-expressing cells leads to macrophage activation, osteoporosis, and early death [J].
Wei, Suwen ;
Dai, Xu-Ming ;
Stanley, E. Richard .
JOURNAL OF LEUKOCYTE BIOLOGY, 2006, 80 (06) :1445-1453
[44]   Giant cell tumour of bone: morphological, biological and histogenetical aspects [J].
Werner, Mathias .
INTERNATIONAL ORTHOPAEDICS, 2006, 30 (06) :484-489
[45]   TOTAL ABSENCE OF COLONY-STIMULATING FACTOR 1 IN THE MACROPHAGE-DEFICIENT OSTEOPETROTIC (OP OP) MOUSE [J].
WIKTORJEDRZEJCZAK, W ;
BARTOCCI, A ;
FERRANTE, AW ;
AHMEDANSARI, A ;
SELL, KW ;
POLLARD, JW ;
STANLEY, ER .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1990, 87 (12) :4828-4832
[46]   Relevance of an in vitro osteoclastogenesis system to study receptor activator of NF-κB ligand and osteoprotegerin biological activities [J].
Wittrant, Y ;
Theoleyre, S ;
Couillaud, S ;
Dunstan, C ;
Heymann, D ;
Rédini, F .
EXPERIMENTAL CELL RESEARCH, 2004, 293 (02) :292-301
[47]   TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells [J].
Wong, BR ;
Rho, JR ;
Arron, J ;
Robinson, E ;
Orlinick, J ;
Chao, M ;
Kalachikov, S ;
Cayani, E ;
Bartlett, FS ;
Frankel, WN ;
Lee, SY ;
Choi, YW .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1997, 272 (40) :25190-25194
[48]   Osteoclast differentiation factor is a ligand for osteoprotegerin osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL [J].
Yasuda, H ;
Shima, N ;
Nakagawa, N ;
Yamaguchi, K ;
Kinosaki, M ;
Mochizuki, S ;
Tomoyasu, A ;
Yano, K ;
Goto, M ;
Murakami, A ;
Tsuda, E ;
Morinaga, T ;
Higashio, K ;
Udagawa, N ;
Takahashi, N ;
Suda, T .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (07) :3597-3602